199 related articles for article (PubMed ID: 26638586)
21. Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.
Yamasaki S; Iida H; Yoshida I; Komeno T; Sawamura M; Matsumoto M; Sekiguchi N; Hishita T; Sunami K; Shimomura T; Takatsuki H; Yoshida S; Otsuka M; Kato T; Kuroda Y; Ooyama T; Suzuki Y; Ohshima K; Nagai H; Iwasaki H
Leuk Lymphoma; 2021 Apr; 62(4):819-827. PubMed ID: 33167741
[TBL] [Abstract][Full Text] [Related]
22. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
[TBL] [Abstract][Full Text] [Related]
23. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
24. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
[TBL] [Abstract][Full Text] [Related]
25. Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.
Martín García-Sancho A; Rodríguez-Pinilla SM; Domingo-Domenech E; Climent F; Sánchez-Garcia J; López Jiménez J; García-Cosío Piqueras M; Castellvi J; González AJ; González de Villambrosia S; Gómez Codina J; Navarro B; Rodríguez G; Borrero JJ; Fraga M; Naves A; Baeza L; Córdoba R
Br J Haematol; 2023 Oct; 203(2):182-193. PubMed ID: 37386897
[TBL] [Abstract][Full Text] [Related]
26. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation.
Rassidakis GZ; Jones D; Lai R; Ramalingam P; Sarris AH; McDonnell TJ; Medeiros LJ
J Pathol; 2003 Jun; 200(2):240-8. PubMed ID: 12754745
[TBL] [Abstract][Full Text] [Related]
27. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Oki Y
PLoS One; 2018; 13(3):e0191461. PubMed ID: 29538376
[TBL] [Abstract][Full Text] [Related]
28. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX.
Nehls O; Okech T; Hsieh CJ; Enzinger T; Sarbia M; Borchard F; Gruenagel HH; Gaco V; Hass HG; Arkenau HT; Hartmann JT; Porschen R; Gregor M; Klump B
Br J Cancer; 2007 May; 96(9):1409-18. PubMed ID: 17426704
[TBL] [Abstract][Full Text] [Related]
29. Prognostic markers in peripheral T-cell lymphoma.
Piccaluga PP; Agostinelli C; Gazzola A; Mannu C; Bacci F; Sabattini E; Pileri SA
Curr Hematol Malig Rep; 2010 Oct; 5(4):222-8. PubMed ID: 20690003
[TBL] [Abstract][Full Text] [Related]
30. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma.
Nelson M; Horsman DE; Weisenburger DD; Gascoyne RD; Dave BJ; Loberiza FR; Ludkovski O; Savage KJ; Armitage JO; Sanger WG
Br J Haematol; 2008 May; 141(4):461-9. PubMed ID: 18341637
[TBL] [Abstract][Full Text] [Related]
33. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Gisselbrecht C; Gaulard P; Lepage E; Coiffier B; Brière J; Haioun C; Cazals-Hatem D; Bosly A; Xerri L; Tilly H; Berger F; Bouhabdallah R; Diebold J
Blood; 1998 Jul; 92(1):76-82. PubMed ID: 9639502
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
[TBL] [Abstract][Full Text] [Related]
36. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
Rüdiger T; Weisenburger DD; Anderson JR; Armitage JO; Diebold J; MacLennan KA; Nathwani BN; Ullrich F; Müller-Hermelink HK;
Ann Oncol; 2002 Jan; 13(1):140-9. PubMed ID: 11863096
[TBL] [Abstract][Full Text] [Related]
37. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the Netherlands.
Meeuwes FO; Brink M; Plattel W; Van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Neelis KJ; Crijns APG; Daniëls LA; Snijders TJF; Vermaat JSP; Huls GA; Nijland M
Haematologica; 2024 Apr; 109(4):1163-1170. PubMed ID: 37794805
[TBL] [Abstract][Full Text] [Related]
38. TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients.
de Pádua Covas Lage LA; Barreto GC; Culler HF; Cavalcante JB; de Oliveira Alves LB; Nardinelli L; Bendit I; Zerbini MCN; Rocha V; Pereira J
Cancer Biomark; 2022; 35(2):179-191. PubMed ID: 36093687
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: Bcl-6 expression might affect progression between these disorders.
Miyoshi H; Sato K; Niino D; Arakawa F; Kimura Y; Kiyasu J; Takeuchi M; Yoshida M; Okada Y; Nakamura Y; Sugita Y; Ohshima K
Am J Clin Pathol; 2012 Jun; 137(6):879-89. PubMed ID: 22586046
[TBL] [Abstract][Full Text] [Related]
40. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
